Autologous haematopoietic stem cell transplantation (HSCT) can be an effective treatment for refractory autoimmune diseases. With reports of the use of allogeneic HSCT emerging, how do these two very different types of stem cell transplantation compare and is allogeneic HSCT advisable?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis
Pediatric Rheumatology Open Access 12 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Greco, R. et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMTR, ADWP, IEWP, and PDWP working parties. Front. Immunol. 10, 1570 (2019).
Thomas, E. D. Pros and cons of stem cell transplantation for autoimmune disease. J. Rheum. 24 (Suppl. 48), 100–102 (1997).
Snowden, J. A. et al. Evolution, trends, outcomes and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 1, 2742–2756 (2017).
Pasquini, M. et al. Transplantation for autoimmune diseases in North and South America: a report of the Center of International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant 18, 1471–1478 (2012).
Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).
Silva, J. M. F. et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2, 777–786 (2018).
Schrezenmeier, H. et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 110, 1397–1400 (2007).
Mielcarek, M. et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127, 1502–1508 (2016).
Sarantopoulos, S., Cardones, A. R. & Sullivan, K. M. How I treat refractory chronic graft-versus-host disease. Blood 133, 1191–1200 (2019).
Sullivan, K. M. et al. Shared decision-making in hematopoietic stem cell transplantation for sickle cell disease. Biol. Blood Marrow Transplant 24, 883–886 (2018).
Acknowledgements
K.M.S. and S.S. would like to thank members in the multidisciplinary team at Duke University Medical Center for their contributions in the care of patients with systemic sclerosis undergoing stem cell transplantation: G. Long, T. Helms and A. Adler, (at the Division of Hematologic Malignancies and Cellular Therapy); A. Shah and E. W. St Clair (at the Division of Rheumatology and Immunology); and A. R. Cardones (at the Department of Dermatology)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Sullivan, K.M., Sarantopoulos, S. Allogeneic HSCT for autoimmune disease: a shared decision. Nat Rev Rheumatol 15, 701–702 (2019). https://doi.org/10.1038/s41584-019-0306-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0306-7
